在晚期肾细胞癌中，伊匹木单抗-纳武单抗联合治疗后用托珠单抗治疗细胞因子释放综合征。
Cytokine release syndrome treated with tocilizumab following ipilimumab-nivolumab combination therapy in advanced renal cell carcinoma.
作者信息
Inoue Toru, Todaka Akiko, Fuse Masahiro, Suzuki Shuntaro, Sejiyama Shinya, Ando Tadasuke, Shin Toshitaka
机构信息
Department of Urology, Faculty of Medicine Oita University Yufu Oita Japan.
Department of Medical Oncology and Hematology, Faculty of Medicine Oita University Yufu Oita Japan.
出版信息
IJU Case Rep. 2024 Nov 29;8(1):64-68. doi: 10.1002/iju5.12812. eCollection 2025 Jan.
INTRODUCTION
Cytokine release syndrome is a rare but potentially life-threatening complication of immune checkpoint inhibitor therapy. Its occurrence in renal cell carcinoma treated with combination therapy is less recognized and poses significant management challenges.
CASE PRESENTATION
A 50-year-old male with metastatic renal cell carcinoma developed severe cytokine release syndrome after receiving ipilimumab-nivolumab combination therapy. The patient presented with high fever, fatigue, and elevated inflammatory markers. Early recognition and prompt intervention with tocilizumab led to rapid clinical improvement.
CONCLUSION
This case highlights the importance of increased awareness, prompt recognition, and targeted management of cytokine release syndrome in renal cell carcinoma patients receiving immune checkpoint inhibitor combination therapy. The rapid response to tocilizumab suggests its potential efficacy in managing immune checkpoint inhibitor-induced cytokine release syndrome.
引言
细胞因子释放综合征是免疫检查点抑制剂治疗罕见但可能危及生命的并发症。其在联合治疗的肾细胞癌中的发生较少被认识到，并且带来了重大的管理挑战。
病例报告
一名50岁转移性肾细胞癌男性患者在接受伊匹木单抗-纳武单抗联合治疗后发生严重细胞因子释放综合征。患者出现高热、疲劳和炎症标志物升高。早期识别并迅速使用托珠单抗进行干预导致临床快速改善。
结论
本病例强调了提高对接受免疫检查点抑制剂联合治疗的肾细胞癌患者细胞因子释放综合征的认识、及时识别和针对性管理的重要性。对托珠单抗的快速反应表明其在管理免疫检查点抑制剂诱导的细胞因子释放综合征方面的潜在疗效。
Zotero 插件